Taurolidine Antiadhesive Properties on Interaction with E. coli; Its Transformation in Biological Environment and Interaction with Bacteria Cell Wall

The taurine amino-acid derivative, taurolidine, bis-(1,1-dioxoperhydro-1,2,4-thiabiazinyl–4)methane, shows broad antibacterial action against gram-positive and gram-negative bacteria, mycobacteria and some clinically relevant fungi. It inhibits, in vitro, the adherence of Escherichia coli and Staphylococcus aureus to human epithelial and fibroblast cells. Taurolidine is unstable in aqueous solution and breaks down into derivatives which are thought to be responsible for the biological activity. To understand the taurolidine antibacterial mechanism of action, we provide the experimental single crystal X-ray diffraction results together with theoretical methods to characterize the hydrolysis/decomposition reactions of taurolidine. The crystal structure features two independent molecules linked through intermolecular H-bonds with one of them somewhat positively charged. Taurolidine in a biological environment exists in equilibrium with taurultam derivatives and this is described theoretically as a 2-step process without an energy barrier: formation of cationic taurolidine followed by a nucleophilic attack of O(hydroxyl) on the exocyclic C(methylene). A concerted mechanism describes the further hydrolysis of the taurolidine derivative methylol-taurultam. The interaction of methylol-taurultam with the diaminopimelic NH2 group in the E. coli bacteria cell wall (peptidoglycan) has a negative ΔG value (−38.2 kcal/mol) but a high energy barrier (45.8 kcal/mol) suggesting no reactivity. On the contrary, taurolidine docking into E. coli fimbriae protein, responsible for bacteria adhesion to the bladder epithelium, shows it has higher affinity than mannose (the natural substrate), whereas methylol-taurultam and taurultam are less tightly bound. Since taurolidine is readily available because it is administered in high doses after peritonitis surgery, it may successfully compete with mannose explaining its effectiveness against bacterial infections at laparoscopic lesions.

[1]  M. Sezik,et al.  An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis. , 2008, The Journal of surgical research.

[2]  Stephan Rogalla,et al.  The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model. , 2007, The Journal of surgical research.

[3]  G. Kristiansen,et al.  Influence of intraperitoneal application of taurolidine/heparin on expression of adhesion molecules and colon cancer in rats undergoing laparoscopy. , 2007, The Journal of surgical research.

[4]  C. Braumann,et al.  Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case , 2006, World journal of surgical oncology.

[5]  W. Hennink,et al.  Identification of formaldehyde-induced modifications in proteins: reactions with insulin. , 2006, Bioconjugate chemistry.

[6]  L. Nici,et al.  The Effects of Taurolidine, a Novel Antineoplastic Agent, on Human Malignant Mesothelioma , 2004, Clinical Cancer Research.

[7]  M Koldehoff,et al.  Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. , 2004, International journal of antimicrobial agents.

[8]  S. Hensen,et al.  Conservation of deduced amino acid sequence of FimH among Escherichia coli of bovine, porcine and avian disease origin. , 2004, Veterinary microbiology.

[9]  D. Chatterjee,et al.  Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer , 2004, Cancer Chemotherapy and Pharmacology.

[10]  M. Brock,et al.  Treatment of glioblastoma with intravenous taurolidine. First clinical experience. , 2004, Anticancer research.

[11]  W. Hennink,et al.  Identification of Formaldehyde-induced Modifications in Proteins , 2004, Journal of Biological Chemistry.

[12]  H. Oğuz,et al.  Intravitreal taurolidine against experimental Staphylococcus epidermidis endophthalmitis in rabbits , 2004, Current eye research.

[13]  C. Braumann,et al.  Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy , 2004, Clinical & Experimental Metastasis.

[14]  H. Guski,et al.  Effects of taurolidine and octreotide on port site and liver metastasis after laparoscopy in an animal model of pancreatic cancer , 2004, Clinical & Experimental Metastasis.

[15]  Charles L. Brooks,et al.  Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm , 2003, J. Comput. Chem..

[16]  H. Lukoff,et al.  The effect of Taurolidine on adherent and floating subpopulations of melanoma cells , 2003, Anti-cancer drugs.

[17]  G. Waksman,et al.  Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection , 2002, Molecular microbiology.

[18]  M. Brock,et al.  The effect of taurolidine on brain tumor cells. , 2002, Anticancer Research.

[19]  H. Redmond,et al.  Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. , 2001, The Journal of surgical research.

[20]  P. Calabresi,et al.  Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. , 2001, Cancer research.

[21]  B. Delley From molecules to solids with the DMol3 approach , 2000 .

[22]  G. Eliopoulos,et al.  Activities of Taurolidine In Vitro and in Experimental Enterococcal Endocarditis , 2000, Antimicrobial Agents and Chemotherapy.

[23]  R. Sabat,et al.  Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. , 1997, American journal of surgery.

[24]  Bernard Delley,et al.  FAST CALCULATION OF ELECTROSTATICS IN CRYSTALS AND LARGE MOLECULES , 1996 .

[25]  P. Tullio,et al.  2,4,7‐Trimethyl‐2,3‐dihydro‐4H‐pyrido[4,3‐e]‐1,2,4‐thiadiazinium 1,1‐Dioxide Iodide , 1995 .

[26]  M. I. Halliday,et al.  Enteral and parenteral anti-endotoxin treatment in experimental colitis. , 1994, Hepato-gastroenterology.

[27]  R. Spagna,et al.  PAUTO– an automatic procedure for crystal structure solution by the Patterson method in the CAOS package , 1994 .

[28]  W. Traub,et al.  Taurolidine: in vitro activity against multiple-antibiotic-resistant, nosocomially significant clinical isolates of Staphylococcus aureus, Enterococcus faecium, and diverse Enterobacteriaceae. , 1993, Chemotherapy.

[29]  K. Sikora,et al.  Tumour inoculation during laparoscopy , 1993, The Lancet.

[30]  Katsuo,et al.  A System of Computer Programs for the Automatic Solution of Co ' sial Structures from X-ray Diffraction Data , 1993 .

[31]  Jackson,et al.  Atoms, molecules, solids, and surfaces: Applications of the generalized gradient approximation for exchange and correlation. , 1992, Physical review. B, Condensed matter.

[32]  R. Endres,et al.  Glycerol-induced unraveling of the tight helical conformation of Escherichia coli type 1 fimbriae , 1992, Journal of bacteriology.

[33]  R. Endres,et al.  Fragmentation of Escherichia coli type 1 fimbriae exposes cryptic D-mannose-binding sites , 1991, Journal of bacteriology.

[34]  K. Krogfelt,et al.  Direct evidence that the FimH protein is the mannose-specific adhesin of Escherichia coli type 1 fimbriae , 1990, Infection and immunity.

[35]  B. Delley An all‐electron numerical method for solving the local density functional for polyatomic molecules , 1990 .

[36]  E. Beachey,et al.  Conservation of the D-mannose-adhesion protein among type 1 fimbriated members of the family Enterobacteriaceae , 1988, Nature.

[37]  G. Thatcher,et al.  Stereoelectronic effects in sulfate diesters and sulfuric acid , 1988 .

[38]  S. Hull,et al.  Attachment of Escherichia coli via mannose- or Gal alpha 1----4Gal beta-containing receptors to human colonic epithelial cells , 1988, Infection and immunity.

[39]  A. Becke,et al.  Density-functional exchange-energy approximation with correct asymptotic behavior. , 1988, Physical review. A, General physics.

[40]  E. Beachey,et al.  Identification of two ancillary subunits of Escherichia coli type 1 fimbriae by using antibodies against synthetic oligopeptides of fim gene products , 1987, Journal of bacteriology.

[41]  S. Gorman,et al.  Electron and light microscopic observations of bacterial cell surface effects due to taurolidine treatment , 1987 .

[42]  S. Gorman,et al.  Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent. , 1987, The Journal of applied bacteriology.

[43]  L. Maurer,et al.  Receptor-binding function of type 1 pili effects bladder colonization by a clinical isolate of Escherichia coli , 1986, Infection and immunity.

[44]  M. Gidley,et al.  The mode of antibacterial action of some ‘masked’ formaldehyde compounds , 1981, FEBS letters.

[45]  D. Schalch,et al.  Identification of a somatomedin‐binding protein produced by a rat hepatoma cell line , 1981, FEBS letters.

[46]  L. Hagberg,et al.  Adhesion, hemagglutination, and virulence of Escherichia coli causing urinary tract infections , 1981, Infection and immunity.

[47]  M. Martí,et al.  [Intraperitoneal and intravenous tauroflex, without antibiotics in the treatment of 40 cases of peritonitis (author's transl)]. , 1978, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis.

[48]  J. L. Lawrence,et al.  The refinement of the crystal structure of a-rhamnose monohydrate , 1971 .